Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cell-Culture vs Egg-Derived Influenza Vaccines in Adults and Elderly (Extension of V58P4)
NCT00579345Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Primary completion
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of TIVc in influenza, sponsored by Novartis. Started Oct 2007; status: completed.
02
Drugs
TIVc
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00579345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00579345.